If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

PULSAR in wAMD and PHOTON in DME/diabetic retinopathy (DR) are double-masked, active-controlled pivotal trials that were conducted in multiple centers globally. In both trials, patients were ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD ... The information on this site has been ...

The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications ... whether as a result of new information, future events, or otherwise.

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ((sBLA)) for Eylea HD injection, 8 mg, to treat macular ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period, reducing the number of injections by half ...

QUASAR trial showed Eylea HD matched vision gains of standard Eylea with less frequent dosing. BofA cuts Regeneron price target to $547, maintains Underperform rating. Learn the top momentum ...

and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...